Evaluating Local Liver Treatment Combined With Systemic Therapy in Patients With Multi-organ Metastatic Colorectal Cancer

What this Trial Is About

Researchers are investigating whether local radical treatment of liver metastases combined with systemic therapy can improve outcomes in patients with colorectal cancer that has spread to multiple organs. The study aims to determine if this approach can benefit survival compared to systemic therapy alone or combined with other local interventions. It also explores risk factors affecting prognosis, assesses quality of life, and evaluates treatment safety. Participants are assigned based on their preference to one of two groups. One group receives radical local treatment of liver metastases through surgery or ablation combined with systemic therapy, which includes chemotherapy, targeted drugs, or immunotherapy. The other group receives systemic therapy alone or combined with local interventional therapies such as transcatheter arterial chemoembolization TACE or hepatic arterial infusion chemotherapy HAIC. Participants will be followed every three months for up to two years. During this time, researchers will monitor overall survival, progression-free survival focused on liver metastases, and any adverse events. Quality of life will be assessed using questionnaires. Regular evaluations will include clinical assessments and laboratory tests to ensure safety and track outcomes throughout the study period.

Local Liver Treatment for Multi-organ Colorectal Cancer Metastases